Arcturus Therapeutics Holdings Inc.

Arcturus Therapeutics is a clinical-stage RNA-medicines company — vaccines for infectious diseases and mRNA therapies for rare liver (OTC deficiency) and respiratory (cystic fibrosis) conditions. The post-COVID revenue cliff has arrived, and the equity thesis now rests on the CF and OTC pipeline.

• Vaccine revenue has collapsed: Q2 came in at $2.96M, down 88% year over year, and Q1 was $610K down 98% — the CSL-partnered COVID-vaccine cash cow is done and analysts don't model meaningful revenue until FY29-30 (~$118M and $224M respectively).
• The June 26 Thermo Fisher CDMO collaboration for ARCT-032 (CF program) is genuine progress — up to $40M of clinical manufacturing plus up to $40M of CRO services, plus commercial-supply optionality on approval — meaning ARCT gets scaled biologics manufacturing without building it.
• Cash burn runs roughly $20-40M per quarter with a $210M market cap, so runway isn't imminent-crisis but isn't luxurious either — a dilutive capital raise inside 12-18 months is on the table if the CF Phase 3 read-out slips.
• The tape has stabilized: +12% off the 50-day average but still at only 11% of the 52-week range on a beta of 2.3 — coiled waiting for the CF Phase 3 initiation call and near-term OTC data.

If ARCT-032 gets a clean Phase 3 initiation and the OTC data reads well, the stock can recover meaningful ground — a clinically-differentiated CF mRNA asset in a rare-disease space with active partner interest is a re-rate story. If OTC disappoints or the Thermo Fisher deal terms come out disappointing on the definitive supply agreement, the coil breaks the other way and dilution risk becomes the tape.